The algorithm of therapeutic and diagnostic measures for gastroesophageal reflux disease

Farber A.V.; Nikonov E.L.

doi:https://doi.org/

Close metadata

Recommended articles:

Diseases of the upper gastrointestinal tract in pregnancy: what should the gastroenterologist consider?. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):30-42

Functional dyspepsia: approaches to diagnosis and treatment in the context of Russian clinical practice. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):43-49

Redo antireflux surgery: a comparative evaluation of laparoscopic and robot-assisted techniques. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):14-20

Esophageal pathology and bronchial asthma: pathogenetic interactions and possibilities for therapy optimization. Russian Journal of Preventive Medicine. 2024;(11):129-134

Proton pump inhibitors: positive and negative properties. On the 45th anniversary of their discovery. Russian Journal of Preventive Medicine. 2024;(11):135-140

Endoscopic assessment of the topographic anatomy of the cardia zone from the lumen of the stomach. Endoscopic Surgery. 2025;(5):28-37

Abstract:

Clinical manifestations of gastroesophageal reflux disease are considered in conjunction with the laboratory and instrumental methods (both obligatory and auxiliary) used for diagnostics of this pathological condition and its possible complications. The main clinical and morphological features of the disease are discussed in conjunction with the measures to be taken in the framework of the therapeutic and diagnostic algorithm from the perspective of evidence-based medicine.

Keywords:

gastroesophageal reflux disease

proton pump inhibitors

histamine H2-receptor antagonists

Barrett's oesophagus

adenocarcinoma of the oesophagus

antireflux measures

Authors:

Farber A.V.

Mezhdunarodnyĭ meditsinskiĭ tsentr "ON KLINIK", Moskovskoe GTU Banka Rossii

Nikonov E.L.

FGBU "Poliklinika #1" Upravleniia delami Prezidenta RF

Scopus AuthorID: 57216680476
ResearcherID: T-9090-2017
ORCID: 0000-0003-3021-6534

Close metadata

References:

Ivashkin V.T., Trukhmanov A.S. Bolezni pishchevoda. Patologicheskaya fiziologiya, klinika, diagnostika, lechenie. M: Triada-Kh 2000.
Isakov V.A. Novaya paradigma GERB i dlitel'naya terapiya ingibitorami protonnogo nasosa. Ekcper i klin gastroenterol 2006; 4: 53-58.
Niemcryk S., Joshua-Gotlib S., Levine D. The outpatient experience of GERD patients in US: An analysis of the 1998-2000 National ambulatory medical care. Gastroenterology 2004; 126 (Suppl. 2): S1213.
Dimenas E., Carlsson G., Glise H. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 1996; 221: 8-13.
Revicki D.A., Wood M., Maton P.N. et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-258.
Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J. Gastroenterol 2003; 98: 31-39.
Lapina T.L. Gastroezofageal'naya reflyuksnaya bolezn': izmenchivaya i konservativnaya pozitsiya. RMZh Bolezni organov pishchevareniya 2009; 9 (1): 1-4.
Fang J.C. Gastroesophageal Reflux Disease. Clin Guid Am Coll Physic 2004; 4: 29.
Kim C., Harrison V., Heidelbaugh J., Nostrant T. Management of Gastroesophageal Reflux Disease. Guidance for Clinocal care. University of Michigan Health System. Guideline 2002; March.
Bueverov A.O. Gastroezofageal'naya reflyuksnaya bolezn': chto delat', kogda neeffektivny ingibitory protonnoi pompy? Ros zhurn gastroenterol, gepatol, koloproktol 2001; 5: 71-73.
DeMeo M.T., Somag S.J. Controversies in the Management of Gastroesophageal Reflux Disease. Gastrointestinal J Club 1992; 1 (2): 3-13.
Dent J., Jones R., Kahrilas P., Talley N. Management of gatroesophageal reflux disease in general practice. BMJ 2001; 322: 344-347.
Lundell L., Dent J., Bennett J. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180.
Ismail-Beigi F., Horton P.F., Pope S.E. Histologic consequences of gastroesophageal reflux in man. Gastroenterology 1970; 58 (2): 163-174.
Chandrasoma P.T., DeMeester T.R. Rationale for surgical over medical treatment for gastro-oesophageal reflux disease. Eur Gastroenterol Hepatol rew 2008; 4 (1): 14-18.
Canto M.J., Setrakian S., Petras R.E. et al. Methylene blue selectively strains intestinal metaplasia in Barrett's esophagus. Gastrontest Endosc 1996; 44: 1-7.
Levine D.S., Haggitt R.C., Blount P.L. et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105: 40-50.
Beck I.T., Champion M.C., Lemire S. et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol. 1997; 11 (suppl B): 7B-20B.
Edwards S.J., Lind T., Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-1736.
Kahrilas P.J. Strategies for medical management of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 775-791.
Vivian E.M., Thompson M.A. Pharmacologic strategies for treating gastroesophageal reflux disease. Clin Ther 2002; 22: 654-672.
Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143 (3): 199-211.
Jacobson B.C., Somers S.C., Fuchs C.S. et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354 (22): 2340-2348.
Castell D.O., Kahrilas P.J., Richter J.E. et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-583.
Carling L., Axelsson C.K., Forssell H. et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther 1998; 12: 985-990.
Dupas J.L., Houcke P., Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterol Clin Biol 2001; 25: 245-250.
Howden C.W., Ballard E.D., Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22: 99-109.
Sharma V.K., Leontiadis G.I., Howden C.W. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15: 227-231.
Thjodleifsson B., Beker J.A., Dekkers C., Bjaaland T., Finnegan V., Humphries T.J. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45: 845-853.
Levy A., Banwait K.S., DiMarino A. et al. Utility of twenty-four esophageal pH monitoring in patients with persistent symptoms on PPI therapy. Gastroenterology 2004; 4 (suppl 2): A-19.
Ishino Y., Sugano K. Acid-suppressive strategy against gastroesophageal reflux diseases and non-erosive reflux diseases: the alternative of proton- pump inhibitors or H2 receptor antagonists.// Nippon Rinsho 2007; 65 (5): 891-894.
Monnikes H., Dorfler H. et al. Does the presence of IBS-like symptoms influence the response of GERD patients to PPI therapy. Gut 2008; 57 (suppl 2): A101.
Targownik L.E., Lix L.M., Prior H.J. et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. Can Med Assoc J 2008; 179: 319-326.
Lachman L., Howden C.W. . Twenty-Four-Hour Intragastric pH: Tolerance Within 5 Days of Continuous Ranitidine Administration. Am J Gastroenterol 2000; 95: 57-61.
Talley N.J. Helicobacter pylori and dyspepsia. Yale J Biol Med 1999; 72 (2-3): 145-151.
Blaser M.J. Ecology of Helicobacter pylori in the human stomach. J Clin Invest 1997; 100: 759-762.
Sonnenberg A., El-Serag H.B. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72 (2-3): 81-92.
Weston A.P., Badr A.S., Hassanein R.S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94 (12): 3413-3419.
Malfertheiner P., Megraud F., O'Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664.
Klinkenberg-Knol E.C., Nelis F., Dent J. et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669.
Lundell L., Miettinen P., Myrvold H.E. et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001; 192: 172-179.
Spechler S.J., Lee E., Ahnen D. et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-2338.
Kuipers E.J., Nelis G.F., Klinkenberg-Knol E.C. et al. Cure of Helicobacter pylori infection in patients with reflux esophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53 (6): 912.
Rekomendatsii Rossiiskoi Gastroenterologicheskoi assotsiatsii po diagnostike i lecheniyu infektsii Helicobacter pylori u vzroslykh. Ros zhurn gastroenterol, gepatol i koloproktol 2012; 22 (1): 87-89.
Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of oesophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146.
Chandrasoma P.T., DeMeester T.R. GERD: From reflux to oesophageal adenocartinoma. San Diego: Academic Press 2006.
Tamhankar A.P., Peters J.H., Portale G. et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004; 8: 890-898.
Viljakka M., Nevalainen J., Isolauri J. Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. Scand J Gastroenterol 1997; 32: 766-772.
Eubanks T.R., Omelanczuk P., Richards C. et al. Outcomes of laparoscopic anti-reflux procedures. Am J Surg 2000; 179: 391-395.
Chang E.Y., Morris C.D., Seltman M.D. et al. The effect of antireflux surgery on oesophageal carcinogenesis in patients with Barrett esophagus; a systematic review. Ann Surg 2007; 246: 11-21.
Parrilla P., deHaro L.F.M., Ortiz A. et al. Long term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-298.
Plany vedeniya bol'nykh. Pod red. O.Yu. At'kova, O.V. Andreevoi, E.I. Polubentsevoi. M: GEOTAR-Media 2007: 528.
Tran T., Lowry A.M., El-Serag H.B. Meta-analysis: the efficacy of over-the-counter gastroesophageal reflux disease therapies. Aliment Pharmacol Ther 2007; 25 (2): 143-153.